ENTRY       D10506            Mixture   Drug
NAME        Fluticasone propionate and formoterol fumarate hydrate;
            Flutiform (TN)
COMPONENT   Fluticasone propionate [DR:D01708], Formoterol fumarate hydrate [DR:D05277]
CLASS       Metabolizing enzyme substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
             DG02924  UGT substrate
REMARK      Therapeutic category: 2290
            ATC code: R03AK11
            Product: D10506<JP>
EFFICACY    Antiasthmatic
COMMENT     Fluticasone propionate is primarily metabolized by CYP3A4.
            Formoterol is primarily metabolized by UDP-glucuronosyltransferase (UGT).
METABOLISM  Enzyme: CYP3A4 [HSA:1576], UGT [KO:K00699]
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             R RESPIRATORY SYSTEM
              R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
               R03A ADRENERGICS, INHALANTS
                R03AK Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics
                 R03AK11 Formoterol and fluticasone
                  D10506  Fluticasone propionate and formoterol fumarate hydrate &lt;JP&gt;
            Therapeutic category of drugs in Japan [BR:br08301]
             2  Agents affecting individual organs
              22  Respiratory organ agents
               229  Miscellaneous
                2290  Miscellaneous
                 D10506  Fluticasone propionate and formoterol fumarate hydrate
            Drug groups [BR:br08330]
             Metabolizing enzyme substrate
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                D10506  Fluticasone propionate and formoterol fumarate hydrate
              DG02924  UGT substrate
               D10506  Fluticasone propionate and formoterol fumarate hydrate
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D10506
DBLINKS     PubChem: 172232599
///
